Envisagenics

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Envisagenics looks to provide means to reduce biomedical data in order to accelerate the creation of new therapeutic solutions. They are focused on finding solutions that help accommodate people who are affected by genetic diseases or cancer, especially if caused by mutations that affect RNA splicing.

Their technologies are designed to accelerate target identification for RNA splicing error discovery, as well as RNA therapeutic design and validation which they perform on their dedicated artificial intelligence discovery platform, and to increase the value of RNA sequencing data.

Funding

Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.

Timeline

May 2018

Envisagenics raises a $1,500,000 grant from National Institutes of Health.

May 2018

Envisagenics raises a $1,000,000 seed round from M12 and Madrona Venture Group.

November 2017

Envisagenics raises a $2,400,000 seed round from Cosine, Dolby Family Ventures, Dynamk Capital, New York State, SV Angel and Third Kind Venture Capital.

April 2017

Envisagenics raises a $350,000 grant from The Thiel Foundation.

August 2015

Envisagenics raises a $225,000 grant from National Institutes of Health.

April 22, 2014

Envisagenics was founded by Maria Luisa Pineda and Martin Akerman.